Nephrodite Wins FDA Breakthrough Device Designation for “Holly”

This investigational implantable, continuous dialysis device has completed its first large animal trials. The company plans to do Good Laboratory Practice studies followed by applying to regulators for first-in-human clinical trials.

Read the full article » | Posted 01-16-2026

Related Articles

• The Lancet Digital Health published results of Humacyte’s Phase III clinical trial of its V007 acellular tissue engineered vessel (ATEV) HD access Posted 09-18-2026
• Humacyte, Inc. announced Robert J. Kossman, MD, FACP, FASN and Prabir Roy-Chaudhury, MD, PhD, FASN have joined the company as advisors. Posted 08-21-2026
• Byonyks on the Move: X-2 and X-3 APD Devices in Development Posted 07-16-2026
• Dr. Ben Reynolds and the Virtual Reality Kidney Dialysis Training Project Posted 06-17-2026